Press Room

Article / May 04, 2004

Do we really need more trade-shows

BioFine Berlin, 4 May 2004

Hovione will be in at the 1st BioFine event in Berlin, so yes we did feel there was space for another show. In fact our thoughts are that some shows may have become too large and far too expensive, trying to be all things to all people, and with their gigantic size working against some of their users. Many of us, tired and with sore feet, wonder why we have to stand in queues waiting for expensive average food. We are looking at Bio-fine as a differentiated show - one that focuses away from commodities and is sensitive to pairing customers with suppliers eager to provide service and know-how.

In giving our best wishes to the managers of BioFine, we would remind them that this is a global industry where English is the lingua franca and the outlook is international. We all have full agendas and tight schedules so please do choose venues where foreigners are welcome, taxis cheap and plentiful, airports near-by and hotels at the convention centre and not a wet 5 (in fact 15) minute walk away! Please time your shows away from other well-established and popular industry events, do consider traditional holidays of the key nations involved, keep away from locations in seasons that are predictably wet and cold. A great show was CPhI 1997 in London in Earl´s Court - everyone spoke English, the walk to the tube was 2 minutes, it was sunny September, and close to all the hotels.

If Bio-fine wants to do really well look to how organisers of US shows do it. Food is free, no queues, no wet walks - and it is inexpensive. Charging attendees makes sure the quality stays high; keeping it small and with a smart market positioning makes sure the right people show up, business is done and time is not wasted. Going forward, security concerns are also a factor, keeping away from big crowds or major cities may be a plus.

At BioFine we will be offering our customers the latest technology we have added to our capabilities: particle size design, from lab to large-scale, with a focus on reproducibility of physical characteristics. Our customers tell us that the galenic interface is where most of our competitors fail. We are doing for particle size and crystal form what we did for injectable grade APIs in the 90´s, becoming a leader and defining bench-marks.

Guy Villax
CEO Hovione
Loures, 4th May 2004

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025